1Janet A, Stacey LB, Mark K, et al. Lenalidomide (LMID) sig nificantly enhances circulating serum levels of IL-2 and IL-15 levels, NK expansion and activation and NK and LAK cytotoxicity in children with refractory/Recurrent solid tumors: a children's oncology group phase Ⅰ consortium report [J]. Blood (ASH Annual Meeting Abstracts), 2008. 112 (3): 107.
2Davies FE, Raje N, Hideshima T, et al. Thalidomide and immunomodulatory derivatives augment natural killer cell cytotoxicity in multiple myeloma [J]. Blood, 2001, 98 (6): 210-216.
3Dredge K, Horsfall R, Robinson SP, et al. Orally administered lenalidomide (CC-5013) is anti-angiogenic in vivo and inhibits endothelial eell migration and Akt phosphorylation in vitro [J]. Microvase Res, 2005, 69 (1 2): 56-63.
4Nicholas M, Constantine SM, Vassiliki P, et al. Apoptotic sig haling induced by immunomodulatnry thalidomide analogs in human multiple myeloma cells: therapeutic implications [ J ]. Blood, 2002, 99 (6):4525-4530.
5Dharminder C, Guilan L, Teru H, et al. NK dependent release of mitochondrial Protein, Smac, during Apoptosis in Multiple Myeloma (MM) Cells [J]. J Biol Chem, 2003, 278 (4):17593-17596.
7List A, Kurtin S, Denise JR, et al. Efficacy of Lenalidomide in Myelodysplastic Syndromes [J]. N. Engl J Med, 2005, 352 (3):549-557.
8Greenberg P, Cox C, LeBeau MM, el al. International scoring system for evaluating prognosis in myelodysplastic syndromes [J]. Blood, 1997, 89 (6): 2079-2088.
9Cheson BD, Bennett JM, Kantarjian H, et al. Report of an international working group to standardize response criteria for myelodysplastic syndromes [J]. Blood, 2000, 96 (6):3671-3674.
10List A, Dewald G, Bennett J, et al. Lenalidomide in the Myelodysplastic Syndrome with Chromosome 5q Deletion [J]. N. Engl J Med, 2006, 355 (3): 1456-1465.
